CDT Equity (CDT) Retained Earnings (2021 - 2026)
CDT Equity's (CDT) quarterly Retained Earnings came in at -$72.4 million in Q1 2026, down 21021.39% YoY from N/an in Q1 2025, and down 5.95% on a QoQ basis from -$68.3 million in Q4 2025.
CDT Equity (CDT) Retained Earnings (2021 - 2026) Analysis & Trends
CDT Equity (CDT) has 6 years of Retained Earnings data on file, last reported at -$72.4 million in Q1 2026.
- Quarterly Retained Earnings fell 21021.39% year-over-year to -$72.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$72.4 million (down 21021.39% YoY) and the FY2025 annual result came in at -$68.3 million, down 16603.62% from the prior year.
- Retained Earnings eased to -$72.4 million in Q1 2026, from -$68.3 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $51.1 million in Q3 2025 to a low of -$72.4 million in Q1 2026.
- A 5-year average of -$8.7 million and a median of $271000.0 in 2024 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2025 — Retained Earnings soared 18741.7% — and 2026, when it plunged 21021.39%.
- Tracing CDT's Retained Earnings over 5 years: stood at $675000.0 in 2022, then soared by 1444.3% to $10.4 million in 2023, then sank by 96.03% to $414000.0 in 2024, then slumped by 16603.62% to -$68.3 million in 2025, then declined by 5.95% to -$72.4 million in 2026.
- The last three Retained Earnings figures came in at -$72.4 million (Q1 2026), -$68.3 million (Q4 2025), and $51.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | CDT Equity | 1.55 Mn | 1.55 Mn | - | 179.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 179.96 Mn |
| Mar 31, 2026 | -72.39 Mn |
| Dec 31, 2025 | -68.33 Mn |
| Sep 30, 2025 | 51.06 Mn |
| Jun 30, 2025 | -39.88 Mn |
| Mar 31, 2025 | 346,000.00 |
| Dec 31, 2024 | 414,000.00 |
| Sep 30, 2024 | 271,000.00 |
| Jun 30, 2024 | 387,000.00 |
| Mar 31, 2024 | 388,000.00 |
| Dec 31, 2023 | 10.42 Mn |
| Sep 30, 2023 | 9.82 Mn |
| Jun 30, 2023 | -14.18 Mn |
| Mar 31, 2023 | -12.44 Mn |
| Dec 31, 2022 | 675,000.00 |
| Sep 30, 2022 | -7.48 Mn |
| Jun 30, 2022 | -3.30 Mn |
| Mar 31, 2022 | -3.08 Mn |
| Dec 31, 2021 | 24,669.00 |